Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine.

Lee NR, Zheng G, Leggas M, Janganati V, Nickell JR, Crooks PA, Bardo MT, Dwoskin L.

J Pharmacol Exp Ther. 2019 Aug 14. pii: jpet.119.258699. doi: 10.1124/jpet.119.258699. [Epub ahead of print]

2.

Pharmacokinetic modeling of the blood-stable camptothecin analog AR-67 in two different formulations.

Liu X, Adane E, Tang F, Leggas M.

Biopharm Drug Dispos. 2019 Sep;40(8):265-275. doi: 10.1002/bdd.2199. Epub 2019 Jul 28.

PMID:
31292985
3.

Bioanalytical method for quantitative determination of mithramycin analogs in mouse plasma by HPLC-QTOF.

Eckenrode JM, Mitra P, Rohr J, Leggas M.

Biomed Chromatogr. 2019 Aug;33(8):e4544. doi: 10.1002/bmc.4544. Epub 2019 May 10.

PMID:
30927450
4.

Validation of a HPLC/MS method for simultaneous quantification of clonidine, morphine and its metabolites in human plasma.

Tang F, Bada H, Ng CM, Leggas M.

Biomed Chromatogr. 2019 Jul;33(7):e4527. doi: 10.1002/bmc.4527. Epub 2019 Mar 20.

PMID:
30830964
5.

Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue, in cancer patients with solid tumors.

Tang F, Tsakalozou E, Arnold SM, Ng CM, Leggas M.

Invest New Drugs. 2019 Feb 28. doi: 10.1007/s10637-019-00744-0. [Epub ahead of print]

PMID:
30820810
6.

Frenolicin B Targets Peroxiredoxin 1 and Glutaredoxin 3 to Trigger ROS/4E-BP1-Mediated Antitumor Effects.

Ye Q, Zhang Y, Cao Y, Wang X, Guo Y, Chen J, Horn J, Ponomareva LV, Chaiswing L, Shaaban KA, Wei Q, Anderson BD, St Clair DK, Zhu H, Leggas M, Thorson JS, She QB.

Cell Chem Biol. 2019 Mar 21;26(3):366-377.e12. doi: 10.1016/j.chembiol.2018.11.013. Epub 2019 Jan 17.

PMID:
30661989
7.

Development of Mithramycin Analogues with Increased Selectivity toward ETS Transcription Factor Expressing Cancers.

Mitra P, Eckenrode JM, Mandal A, Jha AK, Salem SM, Leggas M, Rohr J.

J Med Chem. 2018 Sep 13;61(17):8001-8016. doi: 10.1021/acs.jmedchem.8b01107. Epub 2018 Aug 28.

PMID:
30114371
8.

Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates.

El-Refai SM, Brown JD, Arnold SM, Black EP, Leggas M, Talbert JC.

JCO Clin Cancer Inform. 2017 Nov;1:1-12. doi: 10.1200/CCI.17.00010.

9.

Predicting Student Success Using In-Program Monitoring.

Ferrante AB, Lambert J, Leggas M, Black EP.

Am J Pharm Educ. 2017 Aug;81(6):111. doi: 10.5688/ajpe816111.

10.

Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553).

Arnold SM, Chansky K, Leggas M, Thompson MA, Villano JL, Hamm J, Sanborn RE, Weiss GJ, Chatta G, Baggstrom MQ.

Invest New Drugs. 2017 Oct;35(5):608-615. doi: 10.1007/s10637-017-0441-4. Epub 2017 Feb 16.

11.

Cytotoxic Indolocarbazoles from Actinomadura melliaura ATCC 39691.

Shaaban KA, Elshahawi SI, Wang X, Horn J, Kharel MK, Leggas M, Thorson JS.

J Nat Prod. 2015 Jul 24;78(7):1723-9. doi: 10.1021/acs.jnatprod.5b00429. Epub 2015 Jun 19.

12.

Correction: Drug synergy drives conserved pathways to increase fission yeast lifespan.

Huang X, Leggas M, Dickson RC.

PLoS One. 2015 Apr 29;10(4):e0125857. doi: 10.1371/journal.pone.0125857. eCollection 2015. No abstract available.

13.

Drug synergy drives conserved pathways to increase fission yeast lifespan.

Huang X, Leggas M, Dickson RC.

PLoS One. 2015 Mar 18;10(3):e0121877. doi: 10.1371/journal.pone.0121877. eCollection 2015. Erratum in: PLoS One. 2015;10(4):e0125857.

14.

The combination of ezetimibe and ursodiol promotes fecal sterol excretion and reveals a G5G8-independent pathway for cholesterol elimination.

Wang Y, Liu X, Pijut SS, Li J, Horn J, Bradford EM, Leggas M, Barrett TA, Graf GA.

J Lipid Res. 2015 Apr;56(4):810-20. doi: 10.1194/jlr.M053454. Epub 2015 Jan 29.

15.

Morphine versus clonidine for neonatal abstinence syndrome.

Bada HS, Sithisarn T, Gibson J, Garlitz K, Caldwell R, Capilouto G, Li Y, Leggas M, Breheny P.

Pediatrics. 2015 Feb;135(2):e383-91. doi: 10.1542/peds.2014-2377.

16.

Enzymatic methylation and structure-activity-relationship studies on polycarcin V, a gilvocarcin-type antitumor agent.

Chen JM, Shepherd MD, Horn J, Leggas M, Rohr J.

Chembiochem. 2014 Dec 15;15(18):2729-35. doi: 10.1002/cbic.201402426. Epub 2014 Nov 3.

17.
18.

Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans.

Tsakalozou E, Adane ED, Liang Y, Arnold SM, Leggas M.

Cancer Chemother Pharmacol. 2014 Jul;74(1):45-54. doi: 10.1007/s00280-014-2472-2. Epub 2014 May 8.

PMID:
24807458
19.

Stable RNA nanoparticles as potential new generation drugs for cancer therapy.

Shu Y, Pi F, Sharma A, Rajabi M, Haque F, Shu D, Leggas M, Evers BM, Guo P.

Adv Drug Deliv Rev. 2014 Feb;66:74-89. doi: 10.1016/j.addr.2013.11.006. Epub 2013 Nov 22. Review.

20.

Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients.

Ahmed TA, Hayslip J, Leggas M.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1369-74. doi: 10.1007/s00280-013-2326-3. Epub 2013 Oct 27.

PMID:
24162379
21.

Synthesis and evaluation of a series of benzothiophene acrylonitrile analogs as anticancer agents.

Penthala NR, Sonar VN, Horn J, Leggas M, Yadlapalli JS, Crooks PA.

Medchemcomm. 2013 Jul 1;4(7):1073-1078.

22.

Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery.

Hollis CP, Weiss HL, Leggas M, Evers BM, Gemeinhart RA, Li T.

J Control Release. 2013 Nov 28;172(1):12-21. doi: 10.1016/j.jconrel.2013.06.039. Epub 2013 Aug 3.

23.
24.

Reducing signs of aging and increasing lifespan by drug synergy.

Huang X, Liu J, Withers BR, Samide AJ, Leggas M, Dickson RC.

Aging Cell. 2013 Aug;12(4):652-60. doi: 10.1111/acel.12090. Epub 2013 May 15.

25.

Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer.

Rinehart J, Arnold S, Kloecker G, Lim A, Zaydan MA, Baeker T, Maheshwari JG, Carloss H, Slone S, Shelton B, Croley J, Kvale E, Brooks M, Leggas M.

Cancer Chemother Pharmacol. 2013 May;71(5):1375-83. doi: 10.1007/s00280-013-2111-3. Epub 2013 Mar 9.

PMID:
23475103
26.

Validated LC-MS/MS method for simultaneous determination of SIM and its acid form in human plasma and cell lysate: Pharmacokinetic application.

Ahmed TA, Horn J, Hayslip J, Leggas M.

J Pharm Anal. 2012 Dec;2(6):403-411. doi: 10.1016/j.jpha.2012.07.010. Epub 2012 Aug 7.

27.

Pyramidamycins A-D and 3-hydroxyquinoline-2-carboxamide; cytotoxic benzamides from Streptomyces sp. DGC1.

Shaaban KA, Shepherd MD, Ahmed TA, Nybo SE, Leggas M, Rohr J.

J Antibiot (Tokyo). 2012 Dec;65(12):615-22. doi: 10.1038/ja.2012.81. Epub 2012 Oct 10.

28.

High payload dual therapeutic-imaging nanocarriers for triggered tumor delivery.

Kim JK, Yuan H, Nie J, Yang YT, Leggas M, Potter PM, Rinehart J, Jay M, Lu X.

Small. 2012 Sep 24;8(18):2895-903. doi: 10.1002/smll.201200437. Epub 2012 Jul 6.

29.

Localization and functional characterization of the rat Oatp4c1 transporter in an in vitro cell system and rat tissues.

Kuo KL, Zhu H, McNamara PJ, Leggas M.

PLoS One. 2012;7(6):e39641. doi: 10.1371/journal.pone.0039641. Epub 2012 Jun 29.

30.

Saquayamycins G-K, cytotoxic angucyclines from Streptomyces sp. Including two analogues bearing the aminosugar rednose.

Shaaban KA, Ahmed TA, Leggas M, Rohr J.

J Nat Prod. 2012 Jul 27;75(7):1383-92. doi: 10.1021/np300316b. Epub 2012 Jul 3.

31.

Pharmacologic properties of polyethylene glycol-modified Bacillus thiaminolyticus thiaminase I enzyme.

Liu S, Bae Y, Leggas M, Daily A, Bhatnagar S, Miriyala S, St Clair DK, Moscow JA.

J Pharmacol Exp Ther. 2012 Jun;341(3):775-83. doi: 10.1124/jpet.112.191817. Epub 2012 Mar 19.

PMID:
22431205
32.

Deregulated hepatic metabolism exacerbates impaired testosterone production in Mrp4-deficient mice.

Morgan JA, Cheepala SB, Wang Y, Neale G, Adachi M, Nachagari D, Leggas M, Zhao W, Boyd K, Venkataramanan R, Schuetz JD.

J Biol Chem. 2012 Apr 27;287(18):14456-66. doi: 10.1074/jbc.M111.319681. Epub 2012 Feb 28.

33.

Stereoselective interaction of pantoprazole with ABCG2. II. In vitro flux analysis.

Wang L, Leggas M, Empey PE, McNamara PJ.

Drug Metab Dispos. 2012 May;40(5):1024-31. doi: 10.1124/dmd.111.041616. Epub 2012 Feb 21.

34.

Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats.

Adane ED, Liu Z, Xiang TX, Anderson BD, Leggas M.

Pharm Res. 2012 Jul;29(7):1722-36. doi: 10.1007/s11095-011-0617-0. Epub 2011 Nov 9.

PMID:
22068278
35.

Metabolic pathways of the camptothecin analog AR-67.

Horn J, Milewska M, Arnold SM, Leggas M.

Drug Metab Dispos. 2011 Apr;39(4):683-92. doi: 10.1124/dmd.110.037390. Epub 2010 Dec 28.

36.

An HPLC assay for the lipophilic camptothecin analog AR-67 carboxylate and lactone in human whole blood.

Tsakalozou E, Horn J, Leggas M.

Biomed Chromatogr. 2010 Oct;24(10):1045-51. doi: 10.1002/bmc.1404.

37.

Factors affecting the in vivo lactone stability and systemic clearance of the lipophilic camptothecin analogue AR-67.

Adane ED, Liu Z, Xiang TX, Anderson BD, Leggas M.

Pharm Res. 2010 Jul;27(7):1416-25. doi: 10.1007/s11095-010-0137-3. Epub 2010 Apr 29.

PMID:
20428932
38.

A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies.

Arnold SM, Rinehart JJ, Tsakalozou E, Eckardt JR, Fields SZ, Shelton BJ, DeSimone PA, Kee BK, Moscow JA, Leggas M.

Clin Cancer Res. 2010 Jan 15;16(2):673-80. doi: 10.1158/1078-0432.CCR-09-2429. Epub 2010 Jan 12.

39.

Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia.

Ma P, Dong X, Swadley CL, Gupte A, Leggas M, Ledebur HC, Mumper RJ.

J Biomed Nanotechnol. 2009 Apr;5(2):151-61.

40.

Abrogation of microcystin cytotoxicity by MAP kinase inhibitors and N-acetyl cysteine is confounded by OATPIB1 uptake activity inhibition.

Daily A, Monks NR, Leggas M, Moscow JA.

Toxicon. 2010 Apr 1;55(4):827-37. doi: 10.1016/j.toxicon.2009.11.019. Epub 2009 Nov 24.

PMID:
19944114
41.

Expression of the multi-drug resistance proteins and the pregnane X receptor in treated and untreated retinoblastoma.

Wilson MW, Fraga CH, Rodriguez-Galindo C, Hagedorn N, Leggas ML, Stewart C.

Curr Eye Res. 2009 May;34(5):386-94. doi: 10.1080/02713680902859621.

PMID:
19401882
42.

Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants II: role of plasma esterases in drug release.

Lu X, Howard MD, Talbert DR, Rinehart JJ, Potter PM, Jay M, Leggas M.

AAPS J. 2009 Mar;11(1):120-2. doi: 10.1208/s12248-009-9086-3. Epub 2009 Feb 19. No abstract available.

44.

Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy.

Leggas M, Kuo KL, Robert F, Cloud G, deShazo M, Zhang R, Li M, Wang H, Davidson S, Rinehart J.

Cancer Chemother Pharmacol. 2009 Mar;63(4):731-43. doi: 10.1007/s00280-008-0767-x. Epub 2008 May 24.

PMID:
18500521
45.

Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants: optimization and in vitro characterization.

Lu X, Howard MD, Mazik M, Eldridge J, Rinehart JJ, Jay M, Leggas M.

AAPS J. 2008;10(1):133-40. doi: 10.1208/s12248-008-9013-z. Epub 2008 Mar 4.

46.

Nanotemplate-engineered nanoparticles containing gadolinium for magnetic resonance imaging of tumors.

Zhu D, Lu X, Hardy PA, Leggas M, Jay M.

Invest Radiol. 2008 Feb;43(2):129-40. doi: 10.1097/RLI.0b013e31815878dd.

PMID:
18197065
47.

Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression.

Vore M, Leggas M.

Mol Pharmacol. 2008 Mar;73(3):613-5. Epub 2007 Dec 17.

PMID:
18086804
48.
49.

Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution.

Takenaka K, Morgan JA, Scheffer GL, Adachi M, Stewart CF, Sun D, Leggas M, Ejendal KF, Hrycyna CA, Schuetz JD.

Cancer Res. 2007 Jul 15;67(14):6965-72.

50.

Validation of an HPLC method for analysis of DB-67 and its water soluble prodrug in mouse plasma.

Horn J, Jordan SL, Song L, Roberts MJ, Anderson BD, Leggas M.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Nov 21;844(1):15-22. Epub 2006 Jul 21.

PMID:
16860004

Supplemental Content

Loading ...
Support Center